
Opinion|Videos|November 15, 2024
Importance of Early Referral for CAR T-cell Therapy in Multiple Myeloma and Patient Quality of Life
Panelists discuss how early referral for chimeric antigen receptor T-cell therapy is crucial for patients, as it helps to overcome potential barriers and ensures timely access to this transformative treatment option.
Advertisement
Episodes in this series

Dr Ajai Chari to Dr Martin: As we know, thereare potential barriers or challenges in referring patients to chimeric antigen receptor (CAR) T-cell therapy; why is it important for patients to be referred early for CAR T-cell therapy?
Advertisement
Related to this article

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.

Data from EXCALIBER-RRMM supported FDA accelerated approval of iberdomide plus daratumumab/dexamethasone in R/R multiple myeloma.

The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.

Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.

Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR-TKI-pretreated advanced clear cell renal cell carcinoma.

A new study suggests genomic newborn screening could identify children at risk for early cancers and enable earlier diagnosis and less toxic treatment.

The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
3
Zipalertinib Plus Chemotherapy Improves PFS in First-Line EGFR Exon 20 Insertion+ NSCLC
4
Five Under 5: Top Oncology Videos for the Week of 8/9
5

